Compile Data Set for Download or QSAR
Report error Found 47 Enz. Inhib. hit(s) with all data for entry = 3244
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395282(US10308629, Example 46 | N-{4-[[(4aR,5aR) or (4aS,...)
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395252(US10308629, Example 14 | (4aS,5aS or 4aR,5aR)-3-(P...)
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395255(US10308629, Example 17 | (4aR,5aR or 4aS,5aS)-5a-M...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395280(US10308629, Example 44 | US10308629, Example 45 | ...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395275(US10308629, Example 39 | N-4-[[(7R) or (7S)]-7-Met...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395254(US10308629, Example 16 | rel-(4aR,5aR)-5a-Methyl-3...)
Affinity DataIC50: 6nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395253(US10308629, Example 15 | rel-(4aR,5aR)-N-4-[4-oxo-...)
Affinity DataIC50: 6nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395260(US10308629, Example 22 | 3-(Phenylamino)-2-(pyridi...)
Affinity DataIC50: 6nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395256(US10308629, Example 18 | (4aS,5aS or 4aR,5aR)-5a-M...)
Affinity DataIC50: 6nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395263(US10308629, Example 25 | US10308629, Example 38 | ...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395250(US10308629, Example 12 | rel-(4aR,5aR)-3-(Phenylam...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395282(US10308629, Example 46 | N-{4-[[(4aR,5aR) or (4aS,...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395257(US10308629, Example 19 | N-4-[(4aR,5aR or 4aS,5aS)...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395259(US10308629, Example 21 | 3-(Phenylamino)-2-(pyridi...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395278(US10308629, Example 42 | US10308629, Example 43 | ...)
Affinity DataIC50: 11nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395272(US10308629, Example 36 | (1S,2S)-2-Fluoro-N-4-[[(4...)
Affinity DataIC50: 11nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395285(US10308629, Example 51 | N-{4-[[(4aS,5aS) or (4aR,...)
Affinity DataIC50: 12nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395284(US10308629, Example 50 | N-{4-[[(4aR,5aR) or (4aS,...)
Affinity DataIC50: 13nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395272(US10308629, Example 36 | (1S,2S)-2-Fluoro-N-4-[[(4...)
Affinity DataIC50: 16nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395266(US10308629, Example 30 | 1-Fluoro-N-4-[[(4aS,5aS) ...)
Affinity DataIC50: 17nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395280(US10308629, Example 44 | US10308629, Example 45 | ...)
Affinity DataIC50: 18nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395251(US10308629, Example 13 | (4aR,5aR or 4aS,5aS)-3-(P...)
Affinity DataIC50: 19nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395249(US10308629, Example 11 | rel-(4aR,7aS)-6-Methyl-3-...)
Affinity DataIC50: 19nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395276(US10308629, Example 40 | 2-Fluoro-2-methyl-N-4-[[(...)
Affinity DataIC50: 22nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395278(US10308629, Example 42 | US10308629, Example 43 | ...)
Affinity DataIC50: 22nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395262(US10308629, Example 24 | (7RS)-2-(2-Aminopyridin-4...)
Affinity DataIC50: 25nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395261(US10308629, Example 23 | 2-(2-Aminopyridin-4-yl)-7...)
Affinity DataIC50: 26nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395263(US10308629, Example 25 | US10308629, Example 38 | ...)
Affinity DataIC50: 27nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395268(US10308629, Example 32 | N-4-[rel-(4aS,5aR)-5a-Met...)
Affinity DataIC50: 30nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395270(US10308629, Example 34 | 1-Methyl-N-4-[rel-(4aS,5a...)
Affinity DataIC50: 35nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395248(US10308629, Example 10 | rel-(5R,7S)-2-(3-Fluoropy...)
Affinity DataIC50: 35nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395258(US10308629, Example 20 | N-4-[(4aS,5aS or 4aR,5aR)...)
Affinity DataIC50: 36nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395267(US10308629, Example 31 | 1-Fluoro-N-4-[[(4aR,5aR) ...)
Affinity DataIC50: 52nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395276(US10308629, Example 40 | 2-Fluoro-2-methyl-N-4-[[(...)
Affinity DataIC50: 53nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395244(US10308629, Example 6 | N-4-[rel-(5R,7S)-6,6-Dimet...)
Affinity DataIC50: 63nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395245(US10308629, Example 7 | methyl 4-[rel-(5R,7S)-6,6-...)
Affinity DataIC50: 68nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395271(US10308629, Example 35 | 4-Fluoro-3-methoxy-N-4-[r...)
Affinity DataIC50: 71nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395269(US10308629, Example 33 | N-{4-[rel-(4aR,5aS)-3-Ani...)
Affinity DataIC50: 110nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395243(US10308629, Example 5 | N-4-[rel-(5R,7S)-6,6-Dimet...)
Affinity DataIC50: 115nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395265(US10308629, Example 29 | 1-Fluoro-N-4-[rel-(4aS,5a...)
Affinity DataIC50: 133nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395239(US10308629, Example 1 | rel-(5R,7S)-6,6-Dimethyl-3...)
Affinity DataIC50: 146nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395247(US10308629, Example 9 | 1-cyclopropyl-3-4-[rel-(5R...)
Affinity DataIC50: 240nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395246(US10308629, Example 8 | 1-4-[rel-(5R,7S)-6,6-Dimet...)
Affinity DataIC50: 375nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395264(US10308629, Example 27 | N-{4-[rel-(4aR,5aR)-3-Ani...)
Affinity DataIC50: 630nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395241(US10308629, Example 3 | (5R,7S or 5S,7R)-2-(2-Amin...)
Affinity DataIC50: 648nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395240(US10308629, Example 2 | rel-(5R,7S)-2-(2-Aminopyri...)
Affinity DataIC50: 1.16E+3nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395241(US10308629, Example 3 | (5R,7S or 5S,7R)-2-(2-Amin...)
Affinity DataIC50: 2.93E+3nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent